Cargando…
In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects
Pomalidomide is an immunomodulatory drug, and the dosage of 4 mg per day taken orally on days 1‐21 of repeated 28‐day cycles has been approved in the European Union and the United States to treat patients with relapsed/refractory multiple myeloma. In vitro data showed that pomalidomide is a substrat...
Autores principales: | Li, Yan, Liu, Liangang, Wang, Xiaomin, Zhang, Chengyue, Reyes, Josephine, Hoffmann, Matthew, Palmisano, Maria, Zhou, Simon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175223/ https://www.ncbi.nlm.nih.gov/pubmed/29762875 http://dx.doi.org/10.1002/jcph.1145 |
Ejemplares similares
-
Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects
por: Ogasawara, Ken, et al.
Publicado: (2019) -
Distribution of pomalidomide into semen of healthy male subjects after multiple doses
por: Li, Yan, et al.
Publicado: (2018) -
The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers
por: Liu, Yong, et al.
Publicado: (2014) -
An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
por: Li, Yan, et al.
Publicado: (2018) -
Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)